EyePoint Pharmaceuticals : R&D Day 2024 Presentation

EYEPOINT PHARMACEUTICALS

R&D DAY 2024

U N I V E R S I T Y C L U B | N E W Y O R K C I T Y | J U N E 2 6 , 2 0 2 4

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Legal Disclaimers

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for DURAVYU in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including DURAVYU and EYP-2301; the potential for DURAVYU as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward- looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; termination or breach of current and future license agreements; our dependence on contract research organizations and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

2 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

INTRODUCTIONS AND AGENDA

JAY DUKER, MD I PRESIDENT AND CHIEF EXECUTIVE OFFICER

3 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

R&D Day Speakers: Management

Jay Duker, MD

President and CEO

>30 years managing retinal diseases and is a 12-time clinical trial investigator/co investigator; he has started three companies and has published >345 ophthalmic journal articles. Previous Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston.

4 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

George O. Elston

EVP and CFO

>25 years of diverse financial and executive leadership in the biopharmaceutical sector with strong record of execution across strategic, operational, financial goals to drive shareholder value. He has established strong relationships across wall street and pharma/biotech resulting in transformative company-building and M&A transactions.

Ramiro Ribeiro, MD, PhD

CMO

Extensive experience encompassing clinical practice as a retina specialist, academia and the pharmaceutical industry with a strong track record of successfully bringing novel therapies to patients globally. Previous Head of Clinical Development at Apellis where he successfully led the end-to-end clinical process for FDA approval of SYFOVRE.

R&D Day Speakers: KOL Guest Speakers

Carl D. Regillo, MD, FACS	Yasha S. Modi, MD
Professor of Ophthalmology at Thomas
Jefferson University; Chief of Retina	Associate Professor of Vitreoretinal
Service at Wills Eye Hospital; Founder of	Surgery, Retinal Disease and Uveitis at
Wills Eye Clinical Retina Research Unit in	New York University; Director of Teleretina
Philadelphia and Partner, Mid Atlantic
Retina

5	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	Note: Dr. Modi and Dr. Regillo are paid consultants to EyePoint and are being compensated for their
time in connection with this event.

R&D Day: Agenda (1/2)

Introductions

Company Overview

DURAVYU	(vorolanib intravitreal insert) Overview
DURAVYU	: Phase 2 DAVIO 2 Clinical Results and Sub-
Group Analyses
DURAVYU	: Phase 2 DAVIO 2 12-Month Topline Results

PRESENTATION SPEAKER

Jay Duker, M.D.

Jay Duker, M.D.

Jay Duker, M.D.

Yasha S. Modi, M.D.

Carl D. Regillo, M.D.

		DURAVYU has been conditionally accepted by the FDA as the proprietary name
6	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	for EYP-1901. DURAVYU is an investigational product; it has not been approved by
the FDA. FDA approval and the timeline for potential approval is uncertain.

R&D Day: Agenda (2/2)

DURAVYU : Pivotal Phase 3 Plans for Wet AMD

Early Pipeline

Key Opinion Leader Insights and Discussion

Q&A

Closing Remarks

7 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

PRESENTATION SPEAKER

Jay Duker, M.D.

Ramiro Ribeiro, M.D., Ph.D.

Jay Duker, M.D.

Jay Duker, M.D.

Carl D. Regillo, M.D.

Yasha S. Modi, M.D.

All

Jay Duker, M.D.

Ramiro Ribeiro, M.D., Ph.D.

R&D Day: Agenda

Introductions

Company Overview

DURAVYU	(vorolanib intravitreal insert) Overview
DURAVYU	: Phase 2 DAVIO 2 Clinical Results and Sub-
Group Analyses
DURAVYU	: Phase 2 DAVIO 2 12-Month Topline Results

8 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

PRESENTATION SPEAKER

Jay Duker, M.D.

Jay Duker, M.D.

Jay Duker, M.D.

Yasha S. Modi, M.D.

Carl D. Regillo, M.D.

Phase 3 Clinical Stage Company Leveraging Proven Delivery Technology

Phase 3

Asset

Compelling

Pipeline

Proven

Technology

Strong

Balance

Sheet

10 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

DURAVYU (vorolanib intravitreal insert)

Multi-billion-dollar market opportunities

Proprietary Durasert E drug delivery technology

~$280M of cash and investments1

No debt

1-Unaudited estimate for June 30, 2024